Figure S6 from the E3 Ligase RING1 Targets P53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Jiajia Shen,Pengyu Li,Xuejing Shao,Yang,Xiujun Liu,Min Feng,Qiang Yu,Ronggui Hu,Zhen Wang

DOI: https://doi.org/10.1158/0008-5472.22418187

2023-01-01

Abstract:p53 exerts little effect on RING1 expression and the genetic alterations of p53 and RING1

What problem does this paper attempt to address?

Figure S2 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Jiajia Shen,Pengyu Li,Xuejing Shao,Yang Yang,Xiujun Liu,Min Feng,Qiang Yu,Ronggui Hu,Zhen Wang

DOI: https://doi.org/10.1158/0008-5472.22418202.v1

2023-01-01

Abstract:RING1 binds to p53 in vivo and in vitro, and affects the ubiqutination level of p53
Figure S1 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Jiajia Shen,Pengyu Li,Xuejing Shao,Yang Yang,Xiujun Liu,Min Feng,Qiang Yu,Ronggui Hu,Zhen Wang

DOI: https://doi.org/10.1158/0008-5472.22418205

2023-01-01

Abstract:Efficiency of RING1 knockdown and its effect on the transcriptional activity of p21
Figure S4 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Jiajia Shen,Pengyu Li,Xuejing Shao,Yang Yang,Xiujun Liu,Min Feng,Qiang Yu,Ronggui Hu,Zhen Wang

DOI: https://doi.org/10.1158/0008-5472.22418193

2023-01-01

Abstract:RING1 deficiency results in partial G1 arrest and p21 induction in the cells harboring wild-type p53, and its growth inhibitory effect is partially rescued by p53 silencing
Figure S5 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Jiajia Shen,Pengyu Li,Xuejing Shao,Yang Yang,Xiujun Liu,Min Feng,Qiang Yu,Ronggui Hu,Zhen Wang

DOI: https://doi.org/10.1158/0008-5472.22418190.v1

2023-01-01

Abstract:Knockdown of RING1 suppresses cancer cell migration and inhibits tumor growth in vivo
The E3 Ligase Ring1 Targets P53 For Degradation And Promotes Cancer Cell Proliferation And Survival

Jiajia Shen,Pengyu Li,Xuejing Shao,Yang Yang,Xiujun Liu,Min Feng,Qiang Yu,Ronggui Hu,Zhen Wang

DOI: https://doi.org/10.1158/0008-5472.CAN-17-1805

IF: 11.2

2018-01-01

Cancer Research

Abstract:As a component of the transcriptional repression complex 1 (PRC1), the ring finger protein RING1 participates in the epigenetic regulation in cancer. However, the contributions of RING1 to cancer etiology or development are unknown. In this study, we report that RING1 is a critical negative regulator of p53 homeostasis in human hepatocellular and colorectal carcinomas. RING1 acts as an E3 ubiquitin (Ub) ligase to directly interact with and ubiquitinate p53, resulting in its proteasome-dependent degradation. The RING domain of RING1 was required for its E3 Ub ligase activity. RING1 depletion inhibited the proliferation and survival of the p53 wild-type cancer cells by inducing cell-cycle arrest, apoptosis, and senescence, with only modest effects on p53-deficient cells. Its growth inhibitory effect was partially rescued by p53 silencing, suggesting an important role for the RING1-p53 complex in human cancer. In clinical specimens of hepatocellular carcinoma, RING1 upregulation was evident in association with poor clinical outcomes. Collectively, our results elucidate a novel PRC1-independent function of RING1 and provide a mechanistic rationale for its candidacy as a new prognostic marker and/or therapeutic target in human cancer. (C) 2017 AACR.
Data from Genetic Ablation of rbm38 Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Jin Zhang,Enshun Xu,Cong Ren,Hee Jung Yang,Yanhong Zhang,Wei Sun,Xiangmudong Kong,Weici Zhang,Mingyi Chen,Eric J. Huang,Xinbin Chen

DOI: https://doi.org/10.1158/0008-5472.c.6509990

2023-01-01

Abstract:Abstract Mutant p53 exerts gain-of-function effects that drive metastatic progression and therapeutic resistance, but the basis for these effects remain obscure. The RNA binding protein RBM38 limits translation of mutant p53 and is often altered in tumors harboring it. Here we show how loss of Rbm38 significantly alters cancer susceptibility in mutant p53 knock-in mice by shortening lifespan, altering tumor incidence, and promoting T-cell lymphomagenesis. Loss of Rbm38 enhanced mutant p53 expression and decreased expression of the tumor suppressor Pten, a key regulator of T-cell development. Furthermore, Rbm38 was required for Pten expression via stabilization of Pten mRNA through an AU-rich element in its 3′UTR. Our results suggest that Rbm38 controls T-cell lymphomagenesis by jointly modulating mutant p53 and Pten, with possible therapeutic implications for treating T-cell malignancies. Significance: An RNA-binding protein controls T-cell lymphomagenesis by jointly modulating mutant p53 and PTEN, with possible therapeutic implications for treating T-cell malignancies. Cancer Res; 78(6); 1511–21. ©2018 AACR.
Regulation of P53 signaling in breast cancer by the E3 ubiquitin ligase RNF187

Xin Li,Zhiguo Niu,Chen Sun,Shu Zhuo,Huijie Yang,Xiao Yang,Yun Liu,Cheng Yan,Zhongbo Li,Qi Cao,Guimei Ji,Yinlu Ding,Ting Zhuang,Jian Zhu

DOI: https://doi.org/10.1038/s41419-022-04604-3

2022-02-01

Cell Death and Disease

Abstract:Abstract The tumor suppressor P53 plays critical role in preventing cancer. P53 is rarely mutated and remains functional in luminal-type breast cancer(1). According to current knowledge, wild-type P53 function is tightly controlled by posttranslational modifications, such as ubiquitination. Several ubiquitin ligases have been shown to regulate P53 ubiquitination and protein stability. Here, we report that RNF187, a RING family ubiquitin ligase, facilitates breast cancer growth and inhibits apoptosis by modulating P53 signaling. RNF187 expression was elevated in breast cancer and correlated with breast cancer survival only in the P53 wild-type groups. Bioinformatic analysis showed that the expression of RNF187 was negatively correlated with the expression of P53 target genes, such as IGFBP3 and FAS, in breast cancer. RNF187 depletion inhibited breast cancer growth and facilitated cell death. RNA sequencing analysis indicated that RNF187 could be an important modulator of P53 signaling. Further experiments showed that RNF187 interacts with P53 and promotes its degradation by facilitating its polyubiquitination in breast cancer cells. Interestingly, the in vitro ubiquitin assay showed that RNF187 can directly ubiquitinate P53 in a manner independent of MDM2. These findings reveal a novel direct P53 regulator and a potential therapeutic target for breast cancer.

cell biology
E2F1 Regulates P53r2 Gene Expression in P53-Deficient Cells

Jun-Juan Qi,Ling Liu,Ji-Xiang Cao,Guo-Shun An,Shu-Yan Li,Gang Li,Hong-Ti Jia,Ju-Hua Ni

DOI: https://doi.org/10.1007/s11010-014-2244-7

IF: 3.842

2015-01-01

Molecular and Cellular Biochemistry

Abstract:The p53R2 gene encoding a small subunit of the ribonucleotide reductase has been identified as a p53-inducible gene. Although this gene is discovered as a target for p53 family proteins, the mechanism underlying p53R2 induction by DNA damage in p53-defiencient cells remains to be elucidated. In this study, we demonstrate that transcription factor E2F1 regulates the p53R2 gene expression in p53-deficient cells. We found that p53R2 was a target for E2F1 in DNA damage response (DDR), because ectopic expression of E2F1 in HCT116-p53−/− cells resulted in the increase of p53R2 mRNA and protein expression, and silencing E2F1 diminished its basic expression. Combination of luciferase reporter assay with overexpression or knockdown of E2F1 revealed that E2F1 directly activates the p53R2 gene. Chromatin immunoprecipitation (ChIP) assay showed E2F1 directly bound to the site (TTTGGCGG) at position −684 to −677 of the promoter under E2F1 overexpression or adriamycin (ADR) exposure. Moreover, silencing p53R2 could enhance apoptotic cell death in both HCT116-p53−/− and HCT116-p53+/+ compared to ADR exposure, indicating that p53R2 may protect cancer cell from ADR-induced apoptosis. Together, we have identified a new role of E2F1 in the regulation of p53R2 expression in DDR, and silencing p53R2 may sensitize cancer cells to ADR-induced apoptosis. Our data support the notion that p53R2 is a potential target for cancer therapy. The involvement of E2F1-dependent p53R2 activation in DDR will provide further insight into the induction of p53R2 in p53-deficient cells. These data also give us a deeper understanding of E2F1 role in DDR.
Overexpression of RNF126 Promotes the Development of Colorectal Cancer via Enhancing p53 Ubiquitination and Degradation

Shiyang Wang,Tianlong Wang,Li Wang,Liansheng Zhong,Kai Li

DOI: https://doi.org/10.2147/OTT.S271855

IF: 4

2020-10-28

OncoTargets and Therapy

Abstract:Shiyang Wang, 1, 2 Tianlong Wang, 1 Li Wang, 1 Liansheng Zhong, 3 Kai Li 2 1 Department of Geriatric Surgery, The First Hospital, China Medical University, Shenyang 110001, People's Republic of China; 2 Department of Surgical Oncology, The First Hospital, China Medical University, Shenyang 110001, People's Republic of China; 3 Department of Bioinformatics, College of Life Science, China Medical University, Shenyang 110001, People's Republic of China Correspondence: Kai Li Department of Surgical Oncology, The First Hospital, China Medical University, Shenyang 110001, People's Republic of China Tel +86-13998245233 Email cmu_likai@163.com Background: RING finger protein 126 (RNF126), as a novel E3 ubiquitin ligase, plays an oncogenic role in several solid cancers. But its potential role in colorectal cancer (CRC) that harbored 50% mutant p53, to our knowledge, is rarely reported. Materials and Methods: We investigated the clinical significance and relationship of RNF126 and p53 in CRC tissues and cells. Meanwhile, WB, qRT-PCR, co-IP, MTT, and transwell were used to investigate the function and molecular mechanism of RNF126 in regulating malignant biology in vitro. Results: RNF126 was overexpressed in human CRC specimens, which was tightly associated with tumor size ( P =0.021), T stage ( P =0.030), lymph node metastasis ( P =0.006), TNM stage ( P =0.001), and the poor survival ( P =0.003) of CRC patients. RNF126 had no association with p53 mutation in CRC specimens, and in p53 mutant Colo-205 and SW620 cells. However, in p53 wildtype HCT116 and HCT-8 cells, RNF126 silencing upregulated p53 and p21 but inhibited Rb phosphorylation at Serine 780 (pRb), which was inhibited by p53siRNA. Conversely, RNF126 overexpression downregulated p53 and p21 but promoted pRb expression, which was reversed by a classic proteasome inhibitor, MG132. However, the mRNA levels of above target genes were unchanged, implying a ubiquitination dependent post-translational modification involving in above regulation. Meanwhile, RNF126 was co-immunoprecipitated with p53 and p21 to form a triple complex. RNF126 silencing and overexpression inhibited and promoted p53 ubiquitination and degradation in vitro, respectively. In addition, p53siRNA reversed RNF126 silencing-inhibited cell proliferation, drug resistance, and cell mobility in HCT116 cells. Conversely, MG132 inhibited RNF126 overexpression-promoted above cell biology in HCT-8 cells. Conclusion: Overexpression of RNF126 was remarkably associated with multiple advanced clinical characters of CRC patients independent of mutant p53. RNF126 promotes cell proliferation, mobility, and drug resistance in CRC via enhancing p53 ubiquitination and degradation. Keywords: RING finger protein 126, p53, ubiquitination, colorectal cancer

oncology,biotechnology & applied microbiology
Supplementary Figures from RING-Finger Protein 6 Amplification Activates JAK/STAT3 Pathway by Modifying SHP-1 Ubiquitylation and Associates with Poor Outcome in Colorectal Cancer

Qian Liang,Dan Ma,Xiaoqiang Zhu,Zhenhua Wang,Tian-Tian Sun,Chaoqin Shen,Tingting Yan,Xianglong Tian,TaChung Yu,Fangfang Guo,JiaYin Tang,Yanwei Lin,Huimin Chen,Chao Zhou,Zhizheng Ge,Ming Zhong,Jinxian Chen,Qiang Liu,Zheng Wang,Jing-Yuan Fang,Haoyan Chen,Jie Hong

DOI: https://doi.org/10.1158/1078-0432.22461033.v1

2023-01-01

Abstract:Fig. S1. RNF6 genomic amplification is prevalent in colorectal cancer and correlated with shortened patient survival. Fig. S2. RNF6 is clinically relevant in colorectal cancer. Fig. S3. Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA) in RNF6-higher/lower expression CRC cells and patients, and RNF6 is an oncogenic gene. FigureS4. RNF6 upregulates pSTAT3 via downregulating SHP-1 expression. Figure S5. RNF6 Interacts with SHP-1 and enhances ubiquitylation and degradation of SHP-1. Figure S6. Effectiveness of pSTAT3 inhibitors in treating RNF6-amplified tumors.
The p53-inducible E3 ubiquitin ligase p53RFP induces p53-dependent apoptosis

Jun Huang,Liang-Guo Xu,Ting Liu,Zhonghe Zhai,Hong-Bing Shu

DOI: https://doi.org/10.1016/j.febslet.2005.09.105

2006-02-06

Abstract:Recently, it has been shown that really interesting new gene (RING)-in between ring finger (IBR)-RING domain-containing proteins, such as Parkin and Parc, are E3 ubiquitin ligases and are involved in regulation of apoptosis. In this report, we show that p53-inducible RING-finger protein (p53RFP), a p53-inducible E3 ubiquitin ligase, induces p53-dependent but caspase-independent apoptosis. p53RFP contains an N-terminal RING-IBR-RING domain and an uncharacterized, evolutionally highly conserved C-terminal domain. p53RFP interacts with E2 ubiquitin-conjugating enzymes UbcH7 and UbcH8 but not with UbcH5, and this interaction is mediated through the RING-IBR-RING domain of p53RFP. Interestingly, the conserved C-terminal domain of p53RFP is required and sufficient for p53RFP-mediated apoptosis, suggesting p53RFP-mediated apoptosis does not require its E3 ubiquitin ligase activity. Together with a recent report showing that p53RFP is involved in ubiquitination and degradation of p21, a p53 downstream protein promoting growth arrest and antagonizing apoptosis, our findings suggest that p53RFP is involved in switching a cell from p53-mediated growth arrest to apoptosis.
P53 Suppresses E2f1-Dependent Plk1 Expression Upon Dna Damage by Forming P53-E2f1-Dna Complex

Zhe Zhou,Ji-Xiang Cao,Shu-Yan Li,Guo-Shun An,Ju-Hua Ni,Hong-Ti Jia

DOI: https://doi.org/10.1016/j.yexcr.2013.09.012

IF: 4.145

2013-01-01

Experimental Cell Research

Abstract:E2F1 is implicated in transcriptional activation of polo-like kinase-1 (PLK1), but yet the mechanism is not fully understood. PLK1 suppression plays an important checkpoint role in response to DNA damage. Suppression of the PLK1 gene by binding of p53 to upstream p53RE2 element in the promoter has been recently revealed. Here we report another mechanism, in which p53 interacts with E2F1 to form p53-E2F1-DNA complex repressing E2F1-dependent PLK1 expression. PLK1 was downregulated in cisplatin exposed HCT116p53(+/+) but not HCT116p53(-/-) cells, indicating p53-suppressed PLK1 upon DNA damage. Co-transfection and reporter enzyme assays revealed that p53 suppressed but E2F1 promoted PLK1 gene activation. 5'-Deletion and substitution mutations showed multiple positive cis-elements residing in the PLK1 promoter, of which at least two E2F1 sites at positions -75/-68 and -40/-32 were required for the full activity of the promoter. Combination of 5'-deletion and substitution mutations with over-expression of p53 showed that suppression of the PLK1 gene by p53 was E2F1-dependent: mutation of the E2F1 site at position -75/-68 partially abrogated suppression activity of p53; mutation of E2F1 site at position -40/-32 released from p53 suppression of PLK1 gene completely. Co-immunoprecipitation and electrophoretic mobility shift assay showed that DNA damage promoted p53-E2F1 interaction, thereby creating a p53-E2F1 complex assembly on the PLK1 promoter in vitro. The in vivo formation of p53-E2F1-PLK1 promoter complex upon DNA damage was further evidenced by chromatin immunoprecipitation (ChIP) and re-ChIP. In addition, we showed that suppression of PLK1 by p53 promoted apoptosis. Our data suggest that p53 may interact with E2F1 to form p53-E2F1-DNA complex suppressing E2F1-dependent PLK1 expression. The model of p53 action on E2F1-activated PLK1 gene may explain at least partly how p53 as a suppressor regulates the downstream effects of E2F1 in cellular stresses including DNA damage stress.
Regulated secretion of mutant p53 negatively affects T lymphocytes in the tumor microenvironment

Xiang Dong,Chunlu Li,Chengsi Deng,Jingwei Liu,Danni Li,Tingting Zhou,Xindi Yang,Yunchan Liu,Qiqiang Guo,Yanling Feng,Yang Yu,Zhuo Wang,Wendong Guo,Siyi Zhang,Hongyan Cui,Cui Jiang,Xiwen Wang,Xiaoyu Song,Xun Sun,Liu Cao

DOI: https://doi.org/10.1038/s41388-023-02886-1

IF: 8.756

2023-11-12

Oncogene

Abstract:Several studies have demonstrated the role of the oncogenic mutant p53 in promoting tumor progression; however, there is limited information on the effects of secreted oncogenic mutant p53 on the tumor microenvironment and tumor immune escape. In this study, we found that secretion of mutant p53, determined by exosome content, is dependent on its N-terminal dileucine motif via its binding to β-adaptin, and inhibited by the CHK2-mediated-Ser 20 phosphorylation. Moreover, we observed that the mutant p53 caused downregulation and dysfunction of CD4 + T lymphocytes in vivo and downregulated the levels and activities of rate-limiting glycolytic enzymes in vitro. Furthermore, inhibition of mutant p53 secretion by knocking down AP1B1 or mutation of dileucine motif could reverse the quantity and function of CD4 + T lymphocytes and restrain the tumor growth. Our study demonstrates that the tumor-derived exosome-mediated secretion of oncogenic mutant p53 inhibits glycolysis to alter the immune microenvironment via functional suppression of CD4 + T cells, which may be the underlying mechanism for tumor immune escape. Therefore, targeting TDE-mediated p53 secretion may serve as a potential therapeutic target for cancer treatment.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology
Targeting RING Domains of Mdm2–MdmX E3 Complex Activates Apoptotic Arm of the P53 Pathway in Leukemia/lymphoma Cells

W Wu,C Xu,X Ling,C Fan,B P Buckley,M V Chernov,L Ellis,F Li,I G Muñoz,X Wang

DOI: https://doi.org/10.1038/cddis.2015.358

2015-01-01

Abstract:Reactivation of tumor-suppressor p53 for targeted cancer therapy is an attractive strategy for cancers bearing wild-type (WT) p53 . Targeting the Mdm2–p53 interface or MdmX ((MDM4), mouse double minute 4)–p53 interface or both has been a focus in the field. However, targeting the E3 ligase activity of Mdm2–MdmX really interesting new gene (RING)–RING interaction as a novel anticancer strategy has never been explored. In this report, we describe the identification and characterization of small molecule inhibitors targeting Mdm2–MdmX RING–RING interaction as a new class of E3 ligase inhibitors. With a fluorescence resonance energy transfer-based E3 activity assay in high-throughput screening of a chemical library, we identified inhibitors (designated as MMRis (Mdm2–MdmX RING domain inhibitors)) that specifically inhibit Mdm2–MdmX E3 ligase activity toward Mdm2 and p53 substrates. MMRi6 and its analog MMRi64 are capable of disrupting Mdm2–MdmX interactions in vitro and activating p53 in cells. In leukemia cells, MMRi64 potently induces downregulation of Mdm2 and MdmX. In contrast to Nutlin3a, MMRi64 only induces the expression of pro-apoptotic gene PUMA (p53 upregulated modulator of apoptosis) with minimal induction of growth-arresting gene p21. Consequently, MMRi64 selectively induces the apoptotic arm of the p53 pathway in leukemia/lymphoma cells. Owing to the distinct mechanisms of action of MMRi64 and Nutlin3a, their combination synergistically induces p53 and apoptosis. Taken together, this study reveals that Mdm2–MdmX has a critical role in apoptotic response of the p53 pathway and MMRi64 may serve as a new pharmacological tool for p53 studies and a platform for cancer drug development.
Mutant p53 achieves function by regulating EGR1 to induce epithelial mesenchymal transition

Weipei Meng,Shilong Yu,Yan Li,Haichen Wang,Yuqing Feng,Wanyue Sun,Ying Liu,Shilong Sun,Haifeng Liu

DOI: https://doi.org/10.1016/j.tice.2024.102510

Abstract:The epithelial-mesenchymal transition (EMT) plays a crucial role in lung cancer metastasis, rendering it a promising therapeutic target. Research has shown that non-small cell lung cancer (NSCLC) with p53 mutations exhibits an increased tendency for cancer metastasis. However, the exact contribution of the p53-R273H mutation to tumor metastasis remains uncertain in the current literature. Our study established the H1299-p53-R273H cell model successfully by transfecting the p53-R273H plasmid into H1299 cells. We observed that p53-R273H promotes cell proliferation, migration, invasion, and EMT through CCK-8, wound healing, transwell, western blot and immunofluorescence assays. Notably, the expression of EGR1 was increased in H1299-p53-R273H cells. Knocking out EGR1 in these cells hindered the progression of EMT. ChIP-PCR experiments revealed that p53-R273H binds to the EGR1 promoter sequence, thereby regulating its expression. These findings suggest that p53-R273H triggers EMT by activating EGR1, thereby offering a potential therapeutic approach for lung cancer treatment.
P53 Inactivation Upregulates P73 Expression Through E2F-1 Mediated Transcription.

Chaitali Tophkhane,Shi-He Yang,Yunbo Jiang,Zhikun Ma,Dharmalingam Subramaniam,Shrikant Anant,Shingo Yogosawa,Toshiyuki Sakai,Wan-Guo Liu,Susan Edgerton,Ann Thor,Xiaohe Yang

DOI: https://doi.org/10.1371/journal.pone.0043564

IF: 3.7

2012-01-01

PLoS ONE

Abstract:While p73 overexpression has been associated with increased apoptosis in cancer tissues, p73 overexpressing tumors appear to be of high grade malignancy. Why this putative tumor suppressor is overexpressed in cancer cells and what the function of overexpressed p73 is in breast cancers are critical questions to be addressed. By investigating the effect of p53 inactivation on p73 expression, we found that both protein and mRNA levels of TAp73 were increased in MCF-7/p53siRNA cells, MCF-7/p53mt135 cells and HCT-116/p53−/− cells, as compared to wild type control, suggesting that p53 inactivation by various forms upregulates p73. We showed that p53 knockdown induced p73 was mainly regulated at the transcriptional level. However, although p53 has a putative binding site in the TAp73 promoter, deletion of this binding site did not affect p53 knockdown mediated activation of TAp73 promoter. Chromatin immuno-precipitation (ChIP) data demonstrated that loss of p53 results in enhanced occupancy of E2F-1 in the TAp73 promoter. The responsive sequence of p53 inactivation mediated p73 upregulation was mapped to the proximal promoter region of the TAp73 gene. To test the role of E2F-1 in p53 inactivation mediated regulation of p73 transcription, we found that p53 knockdown enhanced E2F-1 dependent p73 transcription, and mutations in E2F-1 binding sites in the TAp73 promoter abrogated p53 knockdown mediated activation of TAp73 promoter. Moreover, we demonstrated that p21 is a mediator of p53-E2F crosstalk in the regulation of p73 transcription. We concluded that p53 knockdown/inactivation may upregulate TAp73 expression through E2F-1 mediated transcriptional regulation. p53 inactivation mediated upregulation of p73 suggests an intrinsic rescuing mechanism in response to p53 mutation/inactivation. These findings support further analysis of the correlation between p53 status and p73 expression and its prognostic/predictive significance in human cancers.
HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53

Laëtitia K. Linares,Arnd Hengstermann,Aaron Ciechanover,Stefan Müller,Martin Scheffner

DOI: https://doi.org/10.1073/pnas.2030930100

IF: 11.1

2003-09-24

Proceedings of the National Academy of Sciences

Abstract:The RING finger proteins HdmX and Hdm2 share significant structural and functional similarity. Hdm2 is a member of the RING finger family of ubiquitin-protein ligases E3 and targets the tumor suppressor protein p53 for degradation. Although HdmX also binds to p53, HdmX does not induce p53 degradation. Moreover, HdmX has been reported to interfere with p53 degradation in overexpression experiments. To obtain insight into the mechanism by which HdmX interferes with p53 degradation, we studied the effect of HdmX on the E3 activity of Hdm2 in vitro . Surprisingly, this revealed that HdmX stimulates Hdm2-mediated ubiquitination of p53 and that HdmX facilitates ubiquitination of Hdm2 and vice versa. In addition, down-regulation of HdmX expression within cells results in the accumulation of both p53 and Hdm2. Because HdmX alone does not have appreciable E3 activity, these data indicate that HdmX acts as a stimulator, rather than as an inhibitor, of the E3 activity of Hdm2 and that, at least under certain conditions, HdmX is actively involved in the degradation of both p53 and Hdm2.

multidisciplinary sciences
E3 ligase MG53 suppresses tumor growth by degrading cyclin D1

Meng Fang,Hong-Kun Wu,Yumeng Pei,Yan Zhang,Xiangyu Gao,Yanyun He,Gengjia Chen,Fengxiang Lv,Peng Jiang,Yumei Li,Wenwen Li,Peng Jiang,Lin Wang,Jiafu Ji,Xinli Hu,Rui-Ping Xiao

DOI: https://doi.org/10.1038/s41392-023-01458-9

IF: 39.3

2023-07-08

Signal Transduction and Targeted Therapy

Abstract:Due to the essential role of cyclin D1 in regulating transition from G1 to S phase in cell cycle, aberrant cyclin D1 expression is a major oncogenic event in many types of cancers. In particular, the dysregulation of ubiquitination-dependent degradation of cyclin D1 contributes to not only the pathogenesis of malignancies but also the refractory to cancer treatment regiments with CDK4/6 inhibitors. Here we show that in colorectal and gastric cancer patients, MG53 is downregulated in more than 80% of tumors compared to the normal gastrointestinal tissues from the same patient, and the reduced MG53 expression is correlated with increased cyclin D1 abundance and inferior survival. Mechanistically, MG53 catalyzes the K48-linked ubiquitination and subsequent degradation of cyclin D1. Thus, increased expression of MG53 leads to cell cycle arrest at G1, and thereby markedly suppresses cancer cell proliferation in vitro as well as tumor growth in mice with xenograft tumors or AOM/DSS induced-colorectal cancer. Consistently, MG53 deficiency results in accumulation of cyclin D1 protein and accelerates cancer cell growth both in culture and in animal models. These findings define MG53 as a tumor suppressor via facilitating cyclin D1 degradation, highlighting the therapeutic potential of targeting MG53 in treating cancers with dysregulated cyclin D1 turnover.

biochemistry & molecular biology,cell biology

Figure S6 from the E3 Ligase RING1 Targets P53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Figure S2 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Figure S1 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Figure S4 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Figure S5 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

The E3 Ligase Ring1 Targets P53 For Degradation And Promotes Cancer Cell Proliferation And Survival

Data from Genetic Ablation of &lt;i&gt;rbm38&lt;/i&gt; Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Regulation of P53 signaling in breast cancer by the E3 ubiquitin ligase RNF187

E2F1 Regulates P53r2 Gene Expression in P53-Deficient Cells

Overexpression of RNF126 Promotes the Development of Colorectal Cancer via Enhancing p53 Ubiquitination and Degradation

Supplementary Figures from RING-Finger Protein 6 Amplification Activates JAK/STAT3 Pathway by Modifying SHP-1 Ubiquitylation and Associates with Poor Outcome in Colorectal Cancer

The p53-inducible E3 ubiquitin ligase p53RFP induces p53-dependent apoptosis

P53 Suppresses E2f1-Dependent Plk1 Expression Upon Dna Damage by Forming P53-E2f1-Dna Complex

Regulated secretion of mutant p53 negatively affects T lymphocytes in the tumor microenvironment

Targeting RING Domains of Mdm2–MdmX E3 Complex Activates Apoptotic Arm of the P53 Pathway in Leukemia/lymphoma Cells

Mutant p53 achieves function by regulating EGR1 to induce epithelial mesenchymal transition

P53 Inactivation Upregulates P73 Expression Through E2F-1 Mediated Transcription.

HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53

E3 ligase MG53 suppresses tumor growth by degrading cyclin D1

Data from Genetic Ablation of <i>rbm38</i> Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN